RGEN Repligen Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: RGEN

Price (delayed)

$145.555

Market cap

$8.21B

P/E Ratio

194.07

Dividend/share

N/A

EPS

$0.75

Enterprise value

$8.3B

?
Relative Growth: Rel. Growth: 63
Relative Strength: Rel. Strength: 56
Relative Valuation: Rel. Valuation: 26
Relative Profitability: Rel. Profitability: 65

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are ...

Highlights
The stock's P/E is 90% below its last 4 quarters average of 1795.5 and 68% below its 5-year quarterly average of 583.1
RGEN's gross profit is up by 41% YoY and by 4.2% QoQ
The company's net income fell by 19% QoQ
RGEN's EPS is down by 18% since the previous quarter
Sector: Healthcare
Industry: Medical Instruments & Supplies
Website: http://www.repligen.com
Peers: NVAX BMRN NBIX GE

Key stats

What are the main financial stats of RGEN

RGEN stock price

How has the Repligen stock price performed over time
Intraday
3.22%
1 week
11.06%
1 month
2.22%
1 year
22.41%
YTD
-11.17%
QTD
6.68%

Financial performance

How have Repligen's revenue and profit performed over time
Revenue
$785.1M
Gross profit
$422.67M
Operating income
$61.1M
Net income
$41.54M
Gross margin
53.8%
Net margin
5.3%
RGEN's gross profit is up by 41% YoY and by 4.2% QoQ
The net margin has contracted by 21% from the previous quarter
RGEN's gross margin is up by 21% year-on-year
The operating income has increased by 20% from the previous quarter

Price vs fundamentals

How does RGEN's price correlate with its fundamentals

Growth

What is Repligen's growth rate over time

Valuation

What is Repligen stock price valuation
RGEN P/E details
P/E
194.07
P/B
3.89
P/S
10.46
EV/EBIT
111.69
EV/EBITDA
48.36
EV/Sales
10.57
The stock's P/E is 90% below its last 4 quarters average of 1795.5 and 68% below its 5-year quarterly average of 583.1
RGEN's EPS is down by 18% since the previous quarter
The P/B is 21% less than the 5-year quarterly average of 4.8
Repligen's equity has increased by 2.4% YoY
RGEN's P/S is 24% below its 5-year quarterly average of 13.4 and 2.6% below its last 4 quarters average of 10.4
The revenue has grown by 16% YoY and by 2.9% from the previous quarter

Efficiency

How efficient is Repligen business performance
RGEN's ROA is down by 22% since the previous quarter
The return on equity has declined by 20% since the previous quarter
The ROIC has contracted by 8% from the previous quarter
RGEN's return on sales is down by 7% since the previous quarter

Dividends

What is RGEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RGEN.

Financial health

How did Repligen financials performed over time
Repligen's current ratio has increased by 5% YoY
RGEN's quick ratio is up by 3.7% year-on-year
The debt is 67% less than the equity
Repligen's equity has increased by 2.4% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.